Contiguous ABCD1–DXS1357E deletion syndrome (CADDS) is a very rare X-linked genetic condition in which a small piece of the X chromosome is missing at the band Xq28. The missing piece usually includes two side-by-side genes: ABCD1 and DXS1357E, now known as BCAP31. Losing ABCD1 removes a protein that helps move very-long-chain fatty acids (VLCFA) into peroxisomes for breakdown. Losing BCAP31 removes a protein that helps traffic other proteins from the endoplasmic reticulum to the Golgi and helps control cell stress and cell death. Because both genes are missing together, babies often have severe, early-onset illness with cholestatic liver disease, brain white-matter problems (hypo/dysmyelination), profound developmental delay, low muscle tone, dystonia, and sensorineural deafness. Many affected boys become very sick in infancy. The typical lab hallmark is high VLCFA in blood due to loss of ABCD1 function. PubMed+2Wiley Online Library+2
Contiguous ABCD1–DXS1357E deletion syndrome (CADDS) is a very rare X-linked disorder caused by a small missing segment on the X chromosome that removes two neighboring genes at once: ABCD1 and BCAP31 (BCAP31 was historically labeled DXS1357E). Losing ABCD1 stops normal breakdown of very-long-chain fatty acids inside peroxisomes, while losing BCAP31 disrupts protein processing in the endoplasmic reticulum and Golgi apparatus. Babies with CADDS usually have poor growth, weak muscle tone, feeding problems, cholestatic liver disease, sometimes hearing loss and white-matter changes, and often die in infancy. This picture looks more severe than typical adrenoleukodystrophy and shares features with peroxisomal biogenesis disorders. ScienceDirect+2Wiley Online Library+2
Why it differs from classic X-ALD: Pathogenic variants in ABCD1 alone cause X-linked adrenoleukodystrophy (X-ALD). CADDS is different because both ABCD1 and BCAP31 are deleted together, creating a combined, more severe neurometabolic disease with early cholestatic liver failure. NCBI+1
What the two genes do:
• ABCD1 encodes a peroxisomal transporter (ALDP) that moves very-long-chain fatty acids into peroxisomes for breakdown. When it fails, VLCFAs accumulate in tissues. MedlinePlus+1
• BCAP31 helps traffic proteins through the ER and Golgi; its loss causes a syndrome with deafness, dystonia, and hypomyelination (DDCH). In CADDS, the combined loss with ABCD1 produces a more severe course. ScienceDirect+1
Other names
Contiguous ABCD1/BCAP31 (DXS1357E) deletion syndrome
Distal Xq28 microdeletion syndrome involving ABCD1 and BCAP31
“Neonatal phenotype similar to peroxisomal biogenesis disorders” due to ABCD1–DXS1357E deletion (older description in early reports) PubMed+1
Types
Classic two-gene deletion (ABCD1 + BCAP31): The commonest CADDS pattern. This combination strongly links to early cholestatic liver failure and death in the first year if untreated. PubMed+1
Extended Xq28 deletions (ABCD1 + BCAP31 + nearby genes) such as SLC6A8 (creatine transporter) or others. These wider deletions can add more severe intellectual disability, seizures, and metabolic features beyond the core CADDS picture. ResearchGate
BCAP31 (DXS1357E) deficiency without ABCD1 loss: Causes DDCH (deafness, dystonia, cerebral hypomyelination) with liver enzyme flares, but cholestatic liver failure in infancy is far less typical than in CADDS. This helps explain why losing both genes produces the distinct, more lethal CADDS picture. PMC+2MalaCards+2
Female carriers or skewed X-inactivation: Females with the deletion may be unaffected or have milder features, depending on X-inactivation; most reported severe cases are males. (General X-linked principle; ABCD1 is X-linked.) NCBI
Causes
Microdeletion at Xq28: A small missing segment removes ABCD1 and BCAP31 together. This is the direct cause of CADDS. PubMed
Loss of ABCD1 function: Without ABCD1, VLCFA build up and damage brain white matter and adrenal function. NCBI+1
Loss of BCAP31 function: Without BCAP31, protein traffic in cells is disturbed and cell-stress signaling is abnormal, harming brain development and liver function. NCBI
Combined (synergistic) effect: Deleting both genes makes cholestasis and early death more likely than losing BCAP31 alone. PubMed+1
Non-allelic homologous recombination (NAHR): Misaligned repeats during sperm/egg formation can delete the region. (Mechanism inferred for many microdeletions). Pure Amsterdam UMC
De novo deletion: The deletion often happens new in the child, with no family history. (Common in microdeletions and in X-ALD variants). NCBI
Maternal germline mosaicism: A mother can carry the deletion in some egg cells without symptoms and pass it on. (General X-linked deletion risk principle.) NCBI
Unbalanced rearrangement: A parent with a balanced X-chromosome rearrangement can have an affected son with a missing Xq28 segment. (General cytogenetics principle supported by Xq28 case series.) Pure Amsterdam UMC
Wider distal Xq28 loss: Bigger deletions that include SLC6A8 or other nearby genes can worsen neurological and metabolic problems. ResearchGate
Peroxisomal lipid toxicity: VLCFA accumulation damages myelin and liver. NCBI
Hypomyelination pathways: BCAP31-related ER–Golgi stress contributes to poor myelin formation (DDCH mechanism), compounding ABCD1 effects. PMC
Mitochondrial stress cross-talk: BCAP31 loss can disturb apoptosis and cellular energy signaling, adding neuronal vulnerability. PMC
Bile acid pathway disruption: Secondary peroxisomal dysfunction leads to toxic bile acid intermediates that injure the liver in infancy. (Reported in CADDS and related peroxisomal disorders.) PubMed
Adrenal insufficiency: ABCD1 loss may cause poor adrenal hormone production over time. NCBI+1
Creatine transport deficit (if SLC6A8 deleted): Low brain creatine worsens development and seizures. Pure Amsterdam UMC
Immature liver handling of VLCFA and bile acids: Newborn livers are more sensitive, so symptoms start very early. (Explains neonatal onset in reports.) PubMed
Secondary inflammation: Fatty acid and ER-stress signals can trigger inflammation, worsening brain and liver injury. (Mechanism consistent with gene functions.) NCBI
White-matter vulnerability period: Early infancy is a crucial time for myelin; toxic lipids and cell-stress during this window cause lasting harm. PMC
Feeding failure and malnutrition: Severe illness leads to poor intake, which further weakens the child and liver. (Common clinical cascade in neonatal cholestasis.) PubMed
Infections: Recurrent illness stresses an already fragile brain and liver. (Frequent in severe infantile neuro-metabolic disease.) PubMed
Symptoms and signs
Severe illness in early infancy: Babies often become unwell within weeks to months of birth. PubMed
Cholestatic jaundice: Yellow skin and eyes, pale stools, dark urine, itchy skin; due to blocked bile flow inside the liver. PubMed
Liver failure features: Enlarged liver, poor clotting, low sugars, fluid in belly if decompensated. PubMed
Poor feeding and failure to thrive: Difficulty gaining weight and growing. Orpha
Low muscle tone (hypotonia): Feels “floppy,” delayed head control. PubMed
Developmental delay: Late or absent milestones (rolling, sitting, speech). PubMed
Dystonia or abnormal movements: Twisting postures or stiff movements from brain pathway injury. PMC
Sensorineural hearing loss: Trouble hearing that comes from the inner ear or nerve. PMC
Seizures: Spells of abnormal movements or staring. PubMed
Irritability and poor sleep: Often due to neurologic discomfort and cholestatic itch. PubMed
White-matter disease symptoms: Weakness, stiffness/spasticity later on, and profound learning problems when survival allows. PubMed
Feeding/aspiration problems: Coughing or choking with feeds. PubMed
Adrenal problems (sometimes): Vomiting, weakness, low blood pressure if cortisol is low. NCBI+1
Eye/vision concerns: Tracking difficulties due to white-matter involvement. PubMed
Early mortality risk: Especially with severe cholestasis in the first year of life. PubMed
Diagnostic tests
A) Physical examination (bedside observation)
General newborn exam: Look for jaundice, poor weight, enlarged liver, low muscle tone, and developmental red flags. These early clues point to cholestasis plus neurologic disease. PubMed
Growth and nutrition check: Charts show poor weight gain; malnutrition worsens liver disease. Orpha
Neurologic exam: Hypotonia, abnormal reflexes, eye tracking problems, or dystonia suggest central white-matter disease. PubMed
Hearing screening review: Failed newborn screen is common with sensorineural hearing loss; prompts full testing. PMC
Skin and stool color check: Pale or white stools and deep jaundice indicate cholestasis. PubMed
B) Manual/bedside functional tests (simple clinic tools)
Developmental screening tools (e.g., Ages & Stages): Structured questions confirm global delays. PubMed
Tone and posture maneuvers: Gentle passive movement shows low tone or dystonia patterns. PMC
Feeding and swallow assessment: Bedside check for coordination, aspiration, and fatigue during feeds. PubMed
Bedside hearing checks (if formal tests pending): Response to sounds and caregiver voice to flag concerns early. PMC
Vision/oculomotor tracking: Simple face-tracking or object-tracking can reveal early cortical visual difficulties. PubMed
C) Laboratory and pathological tests
Plasma very-long-chain fatty acids (VLCFA): High C26:0 and elevated C24:0/C22:0 and C26:0/C22:0 ratios support ABCD1 loss. This is a key biochemical hallmark. NCBI
Bile-acid intermediates (DHCA/THCA): Accumulation points to peroxisomal β-oxidation defects and helps explain early cholestasis. PubMed
Liver panel: Bilirubin (direct > indirect), high GGT/ALT/AST, low albumin or clotting problems show cholestasis and liver injury. PubMed
Adrenal testing: Morning cortisol and ACTH to screen for developing adrenal insufficiency related to ABCD1 loss. NCBI+1
Genetic testing—chromosomal microarray (CMA): Detects the Xq28 microdeletion spanning ABCD1 and BCAP31. First-line for suspected microdeletions. Pure Amsterdam UMC
Confirmatory sequencing/CNV analysis: Targeted ABCD1 and BCAP31 testing or exome/genome sequencing with deletion/duplication (CNV) calling to define breakpoints and involved genes. Pure Amsterdam UMC
D) Electrodiagnostic tests
EEG: Evaluates seizures and background slowing typical of severe encephalopathy. PubMed
Auditory brainstem response (ABR): Confirms sensorineural hearing loss and quantifies severity. PMC
Visual evoked potentials (VEP): Assesses visual pathway myelination and function; often abnormal in white-matter disease. PubMed
E) Imaging tests
Brain MRI: Shows hypo/dysmyelination or delayed myelin; supports combined ABCD1–BCAP31 effect (CADDS vs isolated conditions). Liver ultrasound evaluates cholestasis and liver structure. Together, imaging guides urgency and care planning. PubMed+1
Non-pharmacological treatments (therapies and others)
Multidisciplinary care pathway
Description: Organize care across neonatology, metabolic genetics, hepatology, neurology, audiology, nutrition, physical and occupational therapy, and palliative care. Purpose: Reduce missed problems, speed decision-making, and align goals with the family. Mechanism: Regular joint reviews and shared protocols reduce fragmentation, ensure timely screening for adrenal/liver issues, and coordinate feeding support and infection prevention. PMC+1Early genetic confirmation and counseling
Description: Chromosomal microarray or exome sequencing to document a deletion spanning ABCD1 and BCAP31, followed by genetic counseling. Purpose: Set accurate expectations, offer carrier testing, and discuss reproductive choices. Mechanism: Identifying a contiguous deletion clarifies prognosis (higher risk of cholestasis and early mortality vs isolated ABCD1), informs surveillance, and enables family planning. ScienceDirect+1Newborn and infant nutritional optimization
Description: High-calorie feeds, careful fat composition, and fat-soluble vitamin support under a dietitian. Purpose: Combat failure to thrive and malabsorption from cholestasis. Mechanism: Structured feeding plans with energy-dense formulas and vitamin A/D/E/K replacement support growth and prevent deficiency complications. PMCSwallowing assessment and safe feeding
Description: Speech-language pathology evaluates suck–swallow–breath coordination and aspiration risk; consider thickened feeds or tube feeding. Purpose: Prevent aspiration pneumonia and ensure reliable calorie delivery. Mechanism: Videofluoroscopic studies guide individualized feeding strategies, reducing hospitalizations. PMCEnteral access (NG/PEG) when needed
Description: If oral intake is unsafe or insufficient, use nasogastric (short-term) or gastrostomy tubes (long-term). Purpose: Maintain growth and medication delivery. Mechanism: Secure access minimizes interruptions from poor feeding or fatigue and supports structured nutrition. PMCPhysiotherapy and positioning
Description: Daily range-of-motion, tone normalization, and posture strategies. Purpose: Limit contractures, improve comfort, and aid respiratory function. Mechanism: Gentle stretching and supportive seating reduce secondary musculoskeletal complications in hypotonia/dystonia. PMCOccupational therapy
Description: Optimize fine-motor activity, adaptive equipment, and caregiver techniques. Purpose: Promote participation and reduce caregiver burden. Mechanism: Task-specific training and splinting support safe handling and comfort. PMCAudiologic screening and habilitation
Description: Newborn hearing screening plus diagnostic ABR; early amplification when appropriate. Purpose: Address sensorineural hearing loss common with BCAP31 involvement. Mechanism: Early auditory input supports communication and bonding even when cognitive delays are severe. PMCVision and neurologic monitoring
Description: Ophthalmology and neurology track eye movements, seizures, and white-matter changes. Purpose: Symptom control and safety. Mechanism: Early recognition of seizures or tone changes guides therapy adjustments. PMCHepatology care for cholestasis
Description: Regular liver enzymes, bilirubin, INR, and ultrasound as advised by hepatology. Purpose: Detect and manage progressive liver disease. Mechanism: Protocolized monitoring supports timely escalation (nutrition, pruritus management, transplant candidacy discussions when appropriate). Wiley Online LibraryFat-soluble vitamin (A, D, E, K) replacement plan
Description: Structured vitamin regimen adjusted to levels. Purpose: Prevent rickets, neuropathy, coagulopathy, and ocular issues from malabsorption. Mechanism: Supplements bypass bile-dependent absorption limitations of cholestasis. PMCRespiratory hygiene and aspiration prevention
Description: Positioning, suction techniques, and chest physiotherapy. Purpose: Reduce pneumonia risk. Mechanism: Mechanical clearance and safe-feeding techniques limit airway contamination. PMCSeizure first-aid training for caregivers
Description: Teach recognition, positioning, timing, and when to seek urgent help. Purpose: Improve safety at home. Mechanism: Standardized action plans reduce delays in acute care. PMCSkin and pressure-injury prevention
Description: Regular turns, moisture control, and protective mattresses. Purpose: Avoid sores in low-mobility infants. Mechanism: Off-loading and skin care reduce breakdown. PMCVaccination according to schedule
Description: Keep routine immunizations current; consider RSV prevention as locally available. Purpose: Reduce severe infections in medically fragile infants. Mechanism: Population-level evidence supports vaccination to prevent respiratory and systemic infections. NCBIMetabolic crisis avoidance
Description: Sick-day plans for hydration, glucose, temperature, and early medical review. Purpose: Prevent decompensation during intercurrent illness. Mechanism: Protocols shorten time to care and maintain energy balance. NCBIAdrenal function screening (as advised)
Description: Some ABCD1 disorders involve adrenal insufficiency; clinicians may screen cortisol/ACTH. Purpose: Detect treatable adrenal issues early. Mechanism: Periodic testing allows prompt hormone replacement if needed. NCBIPalliative care integration
Description: Add palliative specialists early for symptom relief and family support. Purpose: Improve comfort, reduce suffering, and align care with family goals. Mechanism: Expert symptom control and psychosocial support throughout the course. PMCFamily psychosocial support
Description: Counseling, peer groups, and social services. Purpose: Reduce caregiver burnout and support decision-making. Mechanism: Structured support improves coping and care continuity. PMCEthics and goals-of-care conferences
Description: Regular, honest discussions about prognosis and options. Purpose: Ensure care remains consistent with family values. Mechanism: Shared decision-making reduces unwanted interventions at end of life. Wiley Online Library
Drug treatments
Crucial safety note: There are no FDA-approved, disease-modifying medicines specifically for CADDS. The drugs below are supportive or symptom-directed and must be prescribed only by clinicians who know your child’s case. For each medicine, I cite the FDA label on accessdata.fda.gov (where available) to anchor class, core dosing information, and adverse effects; actual dosing in CADDS is individualized.
Ursodiol (ursodeoxycholic acid) – cholestasis support
Class: Bile acid. Purpose: Improve bile flow and cholestatic labs/pruritus. Mechanism: Replaces toxic bile acids with hydrophilic UDCA and protects cholangiocytes. Typical pediatric dosing on label: 10–15 mg/kg/day divided; clinicians may adjust. Timing: Daily with feeds. Key adverse effects: GI upset, rare LFT changes. FDA label: accessdata.fda.gov. PMCCholestyramine – cholestatic itch
Class: Bile acid sequestrant. Purpose: Reduce pruritus by binding bile acids in the gut. Mechanism: Interrupts enterohepatic circulation. Label dosing: Packet-based; pediatric use individualized. Adverse effects: Constipation, fat-soluble vitamin loss (monitor). FDA label: accessdata.fda.gov. PMCRifampin – refractory cholestatic pruritus
Class: Rifamycin antibiotic used here for enzyme induction. Purpose: Lower itch when bile acid sequestration is insufficient. Mechanism: Induces hepatic enzymes to alter pruritogens. Adverse effects: Hepatotoxicity risk—needs close LFT monitoring. FDA label: accessdata.fda.gov. PMCVitamin K (phytonadione) – coagulopathy in cholestasis
Class: Fat-soluble vitamin. Purpose: Prevent/treat bleeding from low vitamin K absorption. Mechanism: Restores gamma-carboxylation of clotting factors. Label: IM/PO formulations; dosing per clinician, guided by INR. Adverse effects: Injection reactions (IM), rare anaphylactoid with rapid IV. FDA label: accessdata.fda.gov. PMCVitamin D (cholecalciferol/ergocalciferol)
Class: Vitamin. Purpose: Prevent rickets and support bone health. Mechanism: Restores 25-OH D. Dosing: Per label and labs; requires careful monitoring in cholestasis. Adverse effects: Hypercalcemia if overdosed. FDA label: accessdata.fda.gov. PMCVitamin A (retinol) and Vitamin E (tocopherol)
Class: Vitamins. Purpose: Prevent ocular/neurologic complications of deficiency. Mechanism: Replace malabsorbed fat-soluble vitamins; water-miscible forms often used. Dosing: Lab-guided; toxicity possible if excessive. Adverse effects: Hypervitaminosis risks. FDA labels: accessdata.fda.gov. PMCLevetiracetam – seizures if present
Class: Antiseizure. Purpose: Control seizures that may occur with severe white-matter disease. Mechanism: Modulates synaptic vesicle protein SV2A. Label pediatric dosing: Weight-based titration. Adverse effects: Somnolence, irritability; monitor behavior. FDA label: accessdata.fda.gov. PMCBaclofen – dystonia/spasticity relief
Class: GABA-B agonist. Purpose: Reduce tone-related discomfort. Mechanism: Inhibits spinal reflexes. Label dosing: Gradual titration; consider intrathecal routes in selected cases. Adverse effects: Sedation, hypotonia. FDA label: accessdata.fda.gov. PMCClonazepam – dystonia/ myoclonus
Class: Benzodiazepine. Purpose: Symptomatic tone and movement control. Mechanism: GABA-A potentiation. Adverse effects: Sedation, respiratory depression risk; cautious pediatric use. FDA label: accessdata.fda.gov. PMCOmeprazole (or similar PPI) – reflux protection with tube feeds
Class: PPI. Purpose: Reduce esophagitis risk in fragile infants. Mechanism: Inhibits gastric H+/K+-ATPase. Adverse effects: Generally well tolerated; monitor for micronutrient effects long-term. FDA label: accessdata.fda.gov. PMCMedium-chain triglyceride (MCT) oil (medical nutrition product)
Class: Medical nutrition therapy. Purpose: Calorie support with better absorption in cholestasis. Mechanism: MCTs bypass bile-dependent micelle formation. Use: Under dietitian supervision. Adverse effects: GI discomfort. (Medical nutrition products; not drug-labeled.) PMCHydroxyzine – adjunct for pruritus and sleep
Class: Antihistamine. Purpose: Reduce itch perception and aid sleep. Mechanism: H1 blockade with central sedation. Adverse effects: Sedation, anticholinergic effects. FDA label: accessdata.fda.gov. PMCAcetaminophen (paracetamol) with careful dosing
Class: Analgesic/antipyretic. Purpose: Fever/comfort management. Mechanism: Central COX modulation. Adverse effects: Hepatotoxicity if overdosed; careful dosing essential in liver disease. FDA label: accessdata.fda.gov. PMCAntibiotics per culture for infections
Class: Various. Purpose: Treat aspiration or device-related infections promptly. Mechanism: Pathogen-targeted therapy reduces complications. Adverse effects: Drug-specific; stewardship needed. FDA labels: accessdata.fda.gov. NCBIPancreatic enzyme replacement if insufficiency is documented
Class: Pancrelipase. Purpose: Support digestion and growth (reported occasionally with combined disorders). Mechanism: Replaces lipase/protease/amylase. Adverse effects: Perianal irritation; dose-dependent risks. FDA label: accessdata.fda.gov. PMCCaffeine citrate – apnea of prematurity if applicable
Class: Respiratory stimulant. Purpose: Reduce apnea/bradycardia spells. Mechanism: Adenosine receptor antagonism. Adverse effects: Tachycardia; dosing is weight-based. FDA label: accessdata.fda.gov. NCBIProbiotics (medical nutrition, not FDA-approved drugs)
Class: Microbiome support. Purpose: GI tolerance; evidence varies. Mechanism: Competes with pathogens and modulates immunity. Use: Only under clinician approval in fragile infants. NCBITopical emollients for skin care
Class: Medical skin care products. Purpose: Prevent skin breakdown. Mechanism: Barrier restoration. Use: Routine nursing care plans. PMCOndansetron – vomiting control during illnesses
Class: 5-HT3 antagonist. Purpose: Reduce vomiting to protect hydration and meds delivery. Adverse effects: Constipation, QT warning in some cases. FDA label: accessdata.fda.gov. NCBIHydrocortisone – only if adrenal insufficiency is proven
Class: Glucocorticoid. Purpose: Replace cortisol when deficient. Mechanism: Restores stress response. Adverse effects: Cushingoid features with overtreatment. FDA label: accessdata.fda.gov; screening guided by specialists. NCBI
Why no “Lorenzo’s oil,” HSCT, or gene therapy here? These are discussed for specific X-ALD contexts (early cerebral ALD). CADDS generally presents as a severe neonatal systemic condition with cholestasis and high infant mortality, so these strategies are not standard for CADDS. Families should discuss any experimental options only within specialized centers. NCBI+1
Dietary molecular supplements
(Use only under a clinician/dietitian; doses are individualized in infants with cholestasis)
Water-miscible Vitamin A – supports vision and immunity when fat absorption is poor. Dose: Lab-guided. Function/Mechanism: Replenishes retinoids for photoreceptors and epithelial integrity. Caution: Toxicity if excess. PMC
Water-miscible Vitamin D3 – bone mineralization. Dose: Based on 25-OH D levels. Mechanism: Restores calcium–phosphate homeostasis. PMC
Natural d-alpha-tocopherol (Vitamin E) water-soluble form – neurologic and hemolysis protection. Dose: Level-guided. Mechanism: Antioxidant in membranes. PMC
Vitamin K drops – clotting factor activation. Dose: INR-guided. Mechanism: Gamma-carboxylation of factors II, VII, IX, X. PMC
MCT oil – calorie dense lipid bypassing bile. Dose: Dietitian-set percentage of total fat. Mechanism: Direct portal absorption. PMC
Essential fatty acids (linoleic/alpha-linolenic) – prevent deficiency with MCT-heavy feeds. Mechanism: Membrane function and eicosanoid balance; careful balancing with cholestasis. PMC
Carnitine (if low) – supports fatty-acid transport. Mechanism: Forms acylcarnitines to shuttle fatty acids; use only if deficiency proven. NCBI
Zinc – growth and wound repair. Dose: Level-guided. Mechanism: Enzyme cofactor; losses may be increased in cholestasis. PMC
Selenium – antioxidant enzyme cofactor. Mechanism: Supports glutathione peroxidase activity; use only with clinical indication. NCBI
Coenzyme Q10 – adjunct antioxidant (evidence limited). Mechanism: Electron transport and membrane antioxidant; consider only in research/clinician-directed settings. NCBI
Drugs as immunity booster / regenerative / stem cell
There are no FDA-approved “immunity boosters” or stem-cell drugs for CADDS. Below are contexts where such ideas arise, with honest guidance.
Hematopoietic stem-cell transplant (HSCT) – not established for CADDS; used in early cerebral X-ALD under strict criteria, not for neonatal cholestasis phenotype. Mechanism: Donor microglia engraftment to slow neuroinflammation in cerebral ALD. Use: Research/ALD-specific programs only. NCBI
Elivaldogene autotemcel (gene therapy for early cerebral ALD) – not applicable to CADDS; indicated for a narrow X-ALD subgroup without HLA-matched donors. Mechanism: Autologous CD34+ cells transduced with ABCD1. Note: Not studied in CADDS phenotype. NCBI
Immunizations – the only truly evidence-based population-level “immune” intervention for fragile infants; follow schedule. Mechanism: Antigen-specific adaptive protection. NCBI
Nutrition-driven immune support – adequate protein, micronutrients (A, D, zinc) per labs. Mechanism: Corrects deficiency-related immune dysfunction. PMC
Physical therapy–driven pulmonary hygiene – reduces infection burden by optimizing airway clearance. Mechanism: Non-drug enhancement of host defenses. PMC
Clinical-trial enrollment where available – mechanism depends on the study; families should explore registries and specialty centers. Mechanism: Access to experimental therapies under oversight. NCBI
Surgeries or procedures (what they are, why done)
Gastrostomy tube (PEG/GT)
Procedure: Endoscopic or surgical placement of a feeding tube through the abdominal wall. Why: Secure nutrition/medication route when oral feeds are unsafe or inadequate. PMCFundoplication (select cases)
Procedure: Wrap part of the stomach around the esophagus to reduce reflux. Why: Prevent aspiration and improve tolerance of feeds if medical therapy fails. PMCCentral venous access
Procedure: Line placement for medications/nutrition when needed. Why: Reliable access during prolonged hospitalizations; carries infection risk. PMCTracheostomy (rare, selected cases)
Procedure: Surgical airway for chronic respiratory failure/aspiration. Why: Facilitate airway clearance and ventilation when less invasive options fail. PMCLiver transplant (extraordinary, highly selected)
Procedure: Replace failing liver. Why: Considered only in specific contexts; CADDS has systemic neuro-metabolic disease, so candidacy is complex and uncommon. Wiley Online Library
Practical preventions
Stick to vaccine schedules and infection-control habits at home and in hospital. NCBI
Use safe-feeding strategies and positioning to prevent aspiration. PMC
Keep regular liver and nutrition follow-ups to catch problems early. Wiley Online Library
Maintain vitamin A/D/E/K plans with lab checks. PMC
Use sick-day plans for early dehydration and fever management. NCBI
Practice meticulous skin care and pressure injury prevention. PMC
Ensure home seizure-safety training if seizures occur. PMC
Regular hearing checks and amplification when indicated. PMC
Adhere to multidisciplinary appointments; keep one care coordinator. PMC
Offer genetic counseling for family planning and carrier testing. ScienceDirect
When to see doctors urgently
Seek immediate care for poor feeding, repeated vomiting, fever, fast breathing, increased sleepiness, seizures, unusual bleeding or bruising, pale or clay-colored stools, deep jaundice, or sudden worsening of tone or movement. These may signal infection, dehydration, liver decompensation, or seizures, which need rapid treatment in CADDS. PMC
What to eat and what to avoid
Do focus on dietitian-designed, energy-dense feeds to support growth. PMC
Prefer formulas with MCT content if advised, to bypass bile-dependent fat absorption. PMC
Include water-miscible fat-soluble vitamin supplements as prescribed. PMC
Use small, frequent feeds if fatigue limits intake. PMC
Avoid high-fat, hard-to-digest feeds unless tailored by the dietitian (fat handling is impaired in cholestasis). PMC
Avoid herbal or over-the-counter “liver cleanses”—they can harm the liver. Consult clinicians first. Wiley Online Library
Keep hydration steady; use oral rehydration plans during illness. NCBI
Avoid honey in infants <1 year (botulism risk). Follow standard infant-feeding safety. NCBI
Avoid alcohol exposure (including via medicines) for liver safety. Check excipients in syrups. Wiley Online Library
Follow all individualized feeding tube care instructions if a tube is placed. PMC
FAQs
1) Is CADDS the same as X-ALD?
No. X-ALD involves ABCD1 alone; CADDS deletes ABCD1 and BCAP31 together, causing a more severe, often neonatal condition with liver cholestasis. Wiley Online Library
2) How is CADDS diagnosed?
By finding a deletion covering both ABCD1 and BCAP31 on chromosome Xq28 using microarray or sequencing with deletion/duplication analysis. ScienceDirect
3) How rare is it?
Extremely rare—only a small number of individuals have been reported worldwide. PMC
4) What causes the symptoms?
Loss of ALDP (ABCD1) leads to VLCFA buildup; loss of BCAP31 disrupts ER/Golgi protein trafficking. Together they cause severe neurometabolic disease. NCBI+1
5) Is there a cure?
No disease-specific cure exists. Care is supportive and multidisciplinary. PMC
6) Are HSCT or gene therapy options?
These are used in select cerebral X-ALD cases; they are not established treatments for CADDS. NCBI
7) Will my child need a feeding tube?
Many infants require tube feeding to maintain growth and safely deliver medicines and vitamins. PMC
8) What about seizures?
If seizures occur, pediatric neurologists use standard antiseizure medicines and safety plans. PMC
9) Why are vitamins A, D, E, and K emphasized?
Cholestasis blocks normal fat-soluble vitamin absorption; targeted replacement prevents serious complications. PMC
10) Is hearing loss common?
Sensorineural hearing loss is linked to BCAP31 involvement and is part of the broader phenotype. PMC
11) What monitoring is needed?
Regular liver panels, coagulation tests, nutrition labs, hearing checks, neurologic assessments, and growth tracking. Wiley Online Library
12) Should we screen adrenal function?
Yes—ABCD1 disorders can involve adrenal insufficiency; clinicians decide frequency and tests. NCBI
13) Can special diets fix the disease?
No diet can cure CADDS, but tailored nutrition improves growth, comfort, and vitamin status. PMC
14) Are there clinical trials?
Trials are rare; your metabolic/genetics team can check registries and discuss suitability. NCBI
15) What is the overall outlook?
Published cases show a severe course with early-life complications; outcomes vary by extent of deletion and supportive resources. Families need ongoing, compassionate, multidisciplinary support. Wiley Online Library+1
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: November 07, 2025.
